Search:

A summary of presentations from the weekly Summit partner webinars

December 14, 2023 – The latest Summit Summary

Updates on COVID-19 and RSV Surveillance in the United States – Erica Rose (CDC) and Natalie J. Thornburg (CDC)

Erica Rose, PhD, and Natalie J. Thornburg, PhD, Coronavirus and Other Respiratory Viruses Division, CDC, gave an update on COVID-19 and RSV Surveillance in the United States.

VIEW SLIDES

Erica Rose

Respiratory Virus Activity Reported to the National Respiratory and Enteric Virus Surveillance System (NREVSS)

See: National Respiratory and Enteric Virus Surveillance System

  • NREVSS is a laboratory-based surveillance platform developed in early 1980’s
  • Data collected on voluntary basis from over 600 public health, academic, and commercial laboratories across U.S.
  • NREVSS asks laboratories to report (per week):
    • Total number of tests conducted
    • Method of detection
    • Number of positive results
  • Lab results based on three general categories
    • Antigen detection
    • Virus isolation or culture
    • PCR
  • Publishes a map of geographic distribution of labs once a quarter on CDC website

National weekly respiratory virus percent positive reported to NREVSS, 12/10/22–12/2/23

  • Rhinoviruses and enteroviruses
    • Highest percent positivity
    • Decreasing in recent weeks
    • Week ending December 2 is 17.7% positive among 131 reporting labs
  • Adenovirus
    • Positivity remained stable in recent weeks
    • Week ending December 2 is 3.8% positive among 121 reporting labs
  • Parainfluenza
    • Decreased slightly in recent weeks
    • Week ending December 2 is 3.4% positive among 124 reporting labs

National trends in PCR test percent positivity for SARS-CoV-2 reported to NREVSS, 5/21/22–12/2/23

  • SARS-CoV-2
    • Trends of PCR test positivity increased by less than 1% (from 10.6% to 11.5%) from 11/25–12/2
    • Test positivity in HHS from week ending December 2
      • Regions 2 and 6 increased by >1%
      • Regions 1, 3, 5, 7, and 10 remained stable
      • Regions 4, 8, and 9 decreased

National weekly smoothed RSV percent positive reported to NREVSS, 12/10/22 through 12/2/23, by HHS Region 

  • National RSV activity decreased by 1% (from 12.8% to 11.8%) from 11/25 to 12/2
  • HHS region 6 had highest percent positivity at 25%
    • Highest percent of pediatric laboratories reporting than other HHS regions
  • Trending back toward pre-pandemic

National Syndromic Surveillance Program (NSSP)

See: National Emergency Department Visits for COVID-19, Influenza, and Respiratory Syncytial Virus

  • National Syndromic Surveillance Program (NSP)
    • Consists of over 6,000 healthcare facilities covering 49 States and DC
    • More than 90% of emergency departments (ED) in the U.S. participate
    • Objective is to monitor near real time influenza-like illness (ILI) and COVID-19-like illness and inpatient status
    • Data includes more than 6 million EHR messages, including chief complaint diagnosis codes, and patient demographics

National Weekly Percentage of U.S. ED Visits with Respiratory Illness Discharge Diagnosis Codes by Age Group,
11/27/22–12/2/23

  • From week 27 to week 48
    • Increase in ED visits diagnosed with COVID-19 in 0–1 age group and 65+ age group seeing the second most ED visits
    • Overall stable trends for COVID-19
    • Decreasing trend among all age groups for ED visits diagnosed with RSV with 0-1 and 2-4 year age group having highest percentage of visits for RSV.

Respiratory Virus Laboratory Emergency Department Network Surveillance (RESP-LENS)

See: RESP LENS Interactive Dashboard

  • RESP-LENS
    • 24 health systems totaling more than 100 EDs across 20 states and D.C.
    • Objective is to provide timely data on primary viruses causing acute respiratory illness (ARI), and monitors trends and seasonality
    • Data links demographics, biologic, clinical information, and disposition
    • Data sources are electronic medical records from patients who visit a participating ED with ILI

National weekly percent positive and number of tests by pathogen reported to RESP-LENS, week ending 12/3/22–12/2/23

  • National trends for COVID-19 and RSV
  • From week 47 to week 48
    • COVID-19 percent positivity 16.1% to 17.6%
    • RSV percent positivity decreased by about 1% from 11.4% to 10.3%
    • All pathogens increased 6–9%

Weekly RSV percent positivity and number of tests by age group, reported to RESP-LENS, week ending 6/17/23–12/2/23

  • SARS-CoV-2 positivity
    • Age 65+ group continues to be highest percent positivity at 25.1%
    • Positivity increased by 1–1.5% from week 47 to 48 in age groups 18–24 years, 25–49 years, and 65+ years
  • RSV positivity
    • Age 0–4 years continues to have highest RSV positivity at 28.3%, down slightly from 28.8% the previous week
    • Age 5–17 years decreased
    • Other age groups remained stable

Respiratory Virus Hospitalization Surveillance Network (RESP-NET) 

Includes RESP-NET: COVID-NET, RSV-NET, FluSurv-NET

COVID-NET: A RESP-NET population-based rates of COVID-19-associated hospitalization surveillance platform

  • Includes positive SARS-CoV-2 rests within 14 days of or during hospitalizations
  • Includes both screening and clinician-driven testing
  • Network consists of more than 300 acute care hospitals in 98 countries and 13 states in 9 out of 10 HHS regions
  • Encompasses about 10% of U.S. population

RSV-NET: A RESP-NET population-based rates of RSV-associated hospitalization surveillance platform

  • Include patients with a positive RSV test withing 14 days of or during hospitalization
  • Includes both screening or clinician-driven testing
  • Network consists of 58 countries and 12 states in 9 out of 10 HHS regions
  • Encompasses about 10% of U.S. population

Overall Rates of Hospitalizations associated with COVID-19, Influenza, and RSV — RESP-NET 10/22–12/2/23

  • Overall COVID-19 hospitalization rates remain elevated and stable
    • Driven largely by adults age 65+ group
  • RSV hospitalization rates continue to increase
  • Flu hospitalization rates are low but increasing in most surveillance sites

COVID-NET – COVID-Associated Hospitalizations

COVID-19-Associated Hospitalization Rates by Age Group – COVID-NET 1/1/23–12/2/23

  • Mostly being driven and remain highest in adults age 65+ group
  • Highest rates in age 0–6 months
  • Elevated in age 6–12 months
  • For adults, hospitalizations highest in age 75+ years

RSV-NET RSV-Associated Hospitalizations

COVID-19-Associated Hospitalization Rates by Age Group – COVID-NET, 1/1/23–12/2/23

  • RSV hospitalizations continue to increase and remain highest and increasing among children age 0–4 years
  • Adults age 65+ years rates are increasing

Overall RSV-Associated Hospitalization Rates – RSV-NET, 2018–2019 through 2023–2024

  • Current season lower hospitalization than same point during last season
  • The 2023–24 season is higher compared to same point during 2021–22 season
  • Little higher than pre-pandemic seasons
  • Appears that seasonality may be moving towards pre-pandemic patterns, but is not there yet.
Natalie J. Thornburg

Nowcast Genomic Surveillance

National SARS-CoV-2 genomic surveillance system: data workflow

  • Genomic data utilized to get an idea of the viruses circulating and how similar they are to the vaccine formulations
  • Sequencing pathway one: National Strain Surveillance System (NS3) ­
    • States collect SARS-CoV-2 positive specimens from state and local public health laboratories and send them to the CDC
    • Of the specimens, some are put into cell culture for isolation and further analysis such as titration and neutralization assays to see if the viruses are circulating, if still neutralized by post-vaccination sera, or if they escape neutralization
  • Sequencing pathway two: CDC Contracting Sequencing Network
    • Private and academic sequencing institutions int the U.S.
    • Informatics analysis
    • Sequences go into public databases
  • Sequencing pathway three: Repository Tagged Sequences
    • S. public health, academic, clinical, and research laboratories
      • Analyze their own data and upload them into public repositories and tag them with baseline sequences
      • Surveillance sequences are tagged In the GISAID/GenBank
    • CDC pulls sequences on routine basis from all sources and includes them in analysis and modeling which go into the Nowcast
      • Updated on a biweekly basis

Nowcast Estimates in the United States through 12/9/23

  • Nowcast webpage lists the viral lineages currently in circulation
  • Naming convention is called Pango
    • Large number of viruses added in sutveillance
    • Get assigned an alias
    • Almost all of the viruses in the Nowcast are of the XBB lineage
      • Vaccine formulation neutralizes viruses well
    • Weighted estimates, which are the proportion of sequences
      • Actual data used
      • Takes a couple of weeks to sequence
      • Use growth rate analysis from the weighted estimate or actual data to calculate growth rates
      • Use the growth rates to project into the present or model into the present
    • Modeled data is not actual sequences
      • Week ending 12/9 predicted most rapidly increasing virus lineage is JN
        • Makes up 15–30% of viruses predicted
        • Different than the other viruses circulating
        • Offshoot of the BA.2.86
        • Evolved differently than XB viruses
          • Many changes in the spike protein compared to XB viruses
        • Some laboratory data suggests sera collected from people who have received the vaccine still neutralize the JN virus
          • Still expect the vaccine to work well with the JN virus since it is related to the vaccine strain
          • All circulating variants are related to current vaccine strain

See: CDC HAN: Urgent Need to Increase Immunization Coverage for Influenza, COVID-19, and RSV and Use of Authorized/Approved Therapeutics in the Setting of Increased Respiratory Disease Activity During the 2023 – 2024 Winter Season (12/14/23)

Questions

Q: Erica, you mentioned there was 25% positive tests for RSV. That seems high, but it doesn’t look like it’s historically high. What is the peak percent positive for RSV?

Erica Rose (CDC): I think the 25% might have been for region six. One thing I didn’t mention, but is important to note, is in laboratory region 6 we have a higher percentage of pediatric facilities reporting than the other regions. So, it looks like region 6 is much higher than the other regions. I think we have to interpret that knowing that we have more pediatric reporters in this region than other regions. We typically see that region 6 can be higher than other regions but it’s hard to know how much of that is due to who is reporting. I think when we look at this season compared to previous seasons it’s hard to know what’s going to happen. We often see around the holidays that it continues to go up, but again, we can see that this season is slightly earlier than previous seasons. A big question we’ve been getting recently is: “has RSV season peaked?” I think the answer is that we don’t know yet. it looks like maybe the season has peaked in the southeast but we still see that RSV is increasing in the northeast and in the northwest. I think we’re not yet ready to say that RSV season has peaked. We may be seeing signs that it’s starting to peak in the southeast.

 

Q: Is the Texas information limited because people aren’t testing, or they’re not seeking medical care, or they don’t have insurance? Should the numbers for Texas be higher? Do you have any Texas specific information?

Erica Rose (CDC): I don’t have state specific information in front of me. I think we have pretty good reporting from Texas and I think Texas is one of the places where we have a lot of pediatric reporters.

 

Q: Do either of you have any last words?

Erica Rose (CDC): I think with COVID-19, one other message is that recently I think we’ve been saying a lot that COVID-19 levels have been stable, and I think we want to emphasize that those stable levels are still pretty high. It’s still important to get the updated COVID-19 vaccine. We are still seeing a lot of hospitalizations and deaths from COVID-19 so I think there may be some burnout from COVID-19, but we’re still seeing trends have been stable recently and they are still elevated.

BACK TO TOP

Intent and Perceptions of the 2023–2024 Updated COVID-19 Vaccine – Chris Voegeli (CDC) and Kayla Calhoun (CDC)

Chris Voegeli, PhD., MPH, Behavioral Scientist, Health Information Integrity Team Lead, CDC, and Kayla Calhoun, MS, Surveillance and Epidemiology Branch, CDC gave a presentation on the intent and perceptions of the 2023–20224 updated COVID-19 vaccine.

Kayla Calhoun

Vaccine Confidence and Demand Updates for COVID-19, Flu, and Respiratory Syncytial Virus (RSV) Vaccines, National Immunization Survey Adult COVID Module (NIS-ACM), and Omnibus Surveys, November 2023

VIEW SLIDES

COVID-19 

COVID-19 Vaccination Receipt and Intent among Adults ≥18 Years of Age by Demographics, Omnibus Surveys, November 2–26, 2023

  • Already or definitely will get vaccinated
    • Tend to be older adults
      • Still less than 1/3 of those 65 years and older have gotten the new vaccine
    • About ¼ of adults definitely will get vaccinated. More likely to be :
      • Of higher income
      • Living in urban or suburban areas
      • White or other non-Hispanic
    • Probably will or unsure if will get vaccinated (movable middle group)
      • The focus of messaging may be most likely to help this group get vaccinated
    • Probably or definitely will not get vaccinated
      • Not typically convincible

COVID-19 Vaccination Concerns and Issues among Adults ≥18 Years of Age by Receipt/Intent, Omnibus Surveys, November 2-26, 2023

  • Already or definitely will get vaccinated
    • 11% concerned about mild side effects
  • Probably will or unsure if will get vaccinated (movable middle group)
    • Top concerns are unknown serious side effects, too busy, or keep forgetting
    • 1/3 say they have no concerns about updated vaccine
    • 15% concerned about mild side effects
  • Probably or definitely will not get vaccinated reported concerns and issues
    • Very reluctant
    • Unknown serious side effects
    • Heart-related issues
    • Don’t trust government or pharma
    • Effectiveness

COVID-19 Vaccination Concerns and Issues among Adults ≥18 Years, Probably Will Get Vaccinated or Unsure, Omnibus Survey, 2022 (bivalent vaccine) & 2023 (updated vaccine)

  • Movable middle group concerns are similar in 2022 and 2023
  • Major issues are fatigue and lack of broader recommendation
  • Slightly more in 2023 mentioned side effects
    • Heart-related
    • Fertility-related
    • Unknown serious side effects
  • Slightly less in 2023 are concerned about effectiveness

Question for movable middle group: What were your specific concerns or issues related to the updated COVID-19 vaccine? (Omnibus surveys, November 2023)

  • Top concern is mild side effects (N=48)
    • Ten mentioned having to plan around school, work, or important events to recover from side effects
  • Not had time (N=26)
    • Having to plan around being sick for a few days after the shot
    • Haven’t had time to schedule an appointment
    • Forgetting
  • Serious side effects (N=32)
    • Mostly heart-related
    • Pre-existing issues causing concern about getting the vaccine
  • Unknown side effects (N=37)
    • Long term side effects outweigh the benefits
    • Side effects of getting the COVID-19 vaccine year after year
  • Effectiveness (N=44)
    • Doesn’t prevent COVID-19
    • COVID-19 vaccines are ineffective this year
  • Vaccine fatigue – tired of getting shots (N=24)
  • Low risk of serious illness (N=21)
    • Don’t know anyone who has had COVID-19 serious illness

COVID-19 Vaccination Concerns and Issues Among Adults ≥18 Years of Age, NIS-ACM

  • Most had little to no difficulty getting the COVID-19 vaccine regardless of COVID-19 vaccination status
  • Only 17-26% had a provider recommendation
    • Reported wider physician recommendation among those vaccinated
  • People who got the updated COVID-19 vaccine
    • Higher vaccine confidence
    • Think it’s important and safe
    • More concerned about getting COVID-19

COVID-19 Vaccination Concerns and Issues among Adults ≥18 Years of Age Who have Not Received a COVID-19 Vaccine since September 14, 2023, by State, NIS-ACM

  • Vaccine safety confidence and prevalence of provider recommendation is higher in the Pacific and northeast than the mountain and southern regions
  • Less than one in four received a provider recommendation

Knowledge of How to Get Free COVID-19 Vaccines among Adults Age ≥18 Years, Omnibus Surveys, November 2-26, 2023

  • Results from the Omnibus Surveys related to the Bridge Access Program
  • About half of the uninsured population said they don’t know how to get a free vaccine compared to about 25% of insured persons

INFLUENZA

Flu Vaccination Receipt and Intent among Adults ≥18 Years of Age by Demographics, Omnibus Surveys, November 2-26, 2023

  • Already vaccinated
    • More people have gotten the flu vaccine than the COVID-19 vaccine
  • 18% say they probably will or are unsure if will get vaccinated (movable middle group)

Flu Vaccination Concerns and Issues among Adults ≥18 Years of Age by Receipt/Intent, Omnibus Surveys, November 2-26, 2023

  • Already or definitely will get vaccinated
    • Over half got it from a pharmacy
    • ¼ got it from a doctor’s office
    • Few from the workplace
  • Probably will or unsure if will get vaccinated (movable middle group)
    • Many adults have no concerns
    • Top issues are time and priority
  • Probably or definitely will not get vaccinated
    • Not worried about flu
    • Don’t think they need the vaccine
    • Not effective
    • A few people don’t trust the government

RSV

RSV Vaccination Receipt and Intent among Adults ≥18 Years of Age by Demographics, Omnibus Surveys, November 2-26, 2023

  • Already or definitely will get vaccinated
    • Adults age 65+ are slightly more likely to have gotten or definitely will get a vaccine compared to persons 60-64 years old
    • Most don’t have concerns
  • Probably will or unsure if will get vaccinated (movable middle group)
    • Most have not gotten the recommendation from their provider, or provider says they don’t need it
    • ¼ say they are not worried about RSV
  • Probably or definitely will not get vaccinated top 3 concerns
    • No specific concerns
    • Medical provider did not recommend
    • Not worried about RSV

Question: If you were due for them and they were offered, would you get more than one of these vaccines in the same visit (COVID-19, Flu, RSV)?

  • Would get at least two of the three vaccines at the same visit?
    • Most are open to coadministration
      • Younger people more likely than age 60+ year group
    • More are resistant to getting RSV vaccine with other vaccines; more people are likely to get COVID-19 and flu vaccine together
    • Reasons people don’t want to get more than one vaccine at the same visit
      • Among age 18–59 year group and age 60+
        • Top reason is they don’t want more side effects
      • Older adults slightly more likely to list more concerns in general

Key Takeaways for COVID-19

  • 76% of adults already received or definitely will get an updated COVID-19 vaccine, and 36% of those who probably will or are unsure if they will get one, had no concerns or issues
  • Top concerns and issues about the updated COVID-19 vaccine among those who probably will or are unsure if they will get one are side effects (both mild and serious) and effectiveness, as well as low risk perception
  • Only 17–26% of respondents received a provider recommendation, but provider recommendation was more widely reported among vaccinated individuals
  • 3% of all adults age 18+ years said they know how to get a free COVID-19 vaccine
    • About half of uninsured adults said they know how to get a free COVID-19 vaccine, compared to almost 4 in 5 insured adults
    • Among all adults who had heard about the Bridge Access Program, 95.7% said they know how to get a free vaccine

Key Takeaways for Flu

  • 79% of adults who already received or definitely will get a flu vaccine, and 32% of those who probably will or are unsure if they will get one, had no concerns or issues
  • Among adults who probably will or are unsure if they will get a flu vaccine, the top issue was they haven’t gotten around to it or haven’t had time
  • Fewer are concerned about side effects and effectiveness of the flu vaccine compared to COVID-19 vaccine
  • About half of adults who received a flu vaccine got one in a store (including pharmacies), about 1 in 4 got one in a doctor’s office or HMO, and about 1 in 10 got one at their workplace

Key Takeaways for RSV

  • 85% of adults who already received or definitely will get an RSV vaccine, and 37% of those who probably will or are unsure if they will get one, had no concerns or issues. Of those who probably or definitely do not plan to get vaccinated, 30% had no concerns or issues.
  • Almost 40% of adults age 60+ years say they probably will or are unsure if they will get an RSV vaccine, suggesting uncertainty about this new vaccine
  • Lack of provider recommendation is a top concern or issue for all who have not yet gotten vaccinated
  • One in four of the most reluctant group said they are “not worried about RSV”

Key Takeaways for Coadministration

  • Most adults are open to receiving multiple vaccines in the same visit
  • This is especially true of younger adults age 18–59 years, who are more likely to report being busy as a reason they haven’t gotten a flu or COVID-19 vaccine
Questions

Q: There’s a large gap for rural and urban COVID-19 and flu coverage, is that gap wider compared to last year and has there been any change this year for the flu vaccine compared to prior years?

Kayla Calhoun (CDC): We have not compared this to previous years, but from month to month for these same questions the urban is usually statistically higher than rural.

 

Q: How can  we look at  the Omnibus survey data?

Kayla Calhoun (CDC): We put together monthly reports with all the data. The questions do change a little bit each month. We have them through August. October should be going up soon. It just it takes a long time to put all this together so that’s why it’s a little bit of a lag. Here is the link to the portal: www.cdc.gov/vaccines/ed/provider-education-resources.html

Chris Voegeli

CDC’s State of Vaccine Confidence Report – Respiratory Viruses Special Report

See: CDC’s State of Vaccine Confidence Insights Report Respiratory Viruses Special Report: COVID-19, RSV, and Flu

See: Resources from Chris Voegeli

See: All past reports

VIEW SLIDES

Theme 1: Public health officials are urging eligible individuals to get vaccinated against COVID-19, RSV, and flu and to immunize infants using monoclonal antibodies

  • People don’t seem to be concerned about these diseases, especially COVID-19
  • Health figures publishing news articles and messages on social media urging vaccines are not getting into people’s minds like they used to
  • People telling others to stay away from vaccination and look for natural remedies, urging exercise and eating healthy as the alternative to vaccinating
  • Commonly asked questions:
    • Can COVID-19, RSV, and flu vaccines be coadministered?
      • People talk about negative experiences
    • Why should individuals be concerned about respiratory virus season?
      • People think it’s an issue mostly for the older or younger populations
    • Inaccurate health information themes:
      • Misinformation themes – circulation of all three viruses at the same time is not real and a plot to sell more vaccines or get control over the population (conspiracy theories)

Theme 2: Consumers are becoming less concerned with COVID-19. Some social media users are reluctant to receive the 2023-2024 updated COVID-19 vaccine

  • Consumers are becoming less concerned with COVID-19 illness
  • Some social media users are reluctant to receive the messages
  • 63% of respondents said they don’t follow COVID-19 cases very closely or at all
  • 31% were worried about COVID-19
  • 69% said they weren’t worried about COVID-19
  • August 2023 KFF Health Misinformation Tracking Poll:
    • 65% adults had heard COVID-19 vaccines have caused thousands of sudden deaths in otherwise healthy people
      • 34% say they believe that the false claim is probably or definitely true
    • A lot of parents associated with schools share concerns on social media
      • Users claim COVID-19 vaccines are not necessary or effective
      • Concerned with harmful side effects like myocarditis and blood clots
    • Commonly asked questions
    • Will the updated COVID-19 vaccine for the 2023-2024 season be free?
    • Why do individuals need to receive the 2023-2024 updated COVID-19 vaccine if they’ve already received previous booster doses?
    • Who is eligible for the 2023-2024 updated COVID-19 vaccine for the fall 2023-2024 season?
    • Where can I find COVID-19 vaccines?
    • Inaccurate health information themes:
      • Vaccinated individuals are more likely to get COVID-19 than unvaccinated

Theme 3: Consumers and social media users are discussing the recently FDA-approved RSV vaccines for pregnant individuals and adults 60 years of age and older

  • Confusion over the difference between the RSV vaccine and the RSV preventative monoclonal antibodies
  • One third of respondents thought their infant would definitely or probably be infected with RSV within a year
  • Data from the National Poll on Healthy Aging
    • Half of age 60–80 years group have heard about the new RSV vaccine
    • 21% were interested in getting it
  • Commonly asked questions:
  • How much will RSV vaccines cost consumers?
  • Is the RSV vaccine an mRNA vaccine?
  • What are the side effects of the RSV vaccine?
  • Inaccurate health information themes:
  • RSV vaccines had to be developed only because widespread COVID- 19 vaccination created RSV
  • Some social media users believe RSV vaccines are not safe for pregnant individuals and their developing fetuses
  • Some social media users believe RSV vaccine did not undergo adequate testing and clinical trials before FDA approval

Theme 4: Consumers are concerned about side effects from flu vaccines. Additionally, social media users are discussing egg proteins present in flu vaccines.

  • Consumers are concerned about the side effects from flu
  • Concerns about egg proteins in the flu vaccines
  • Some social media users are sharing belief that the flu vaccine will result in a worse case of flu
  • Don’t trust pharmaceutical companies
  • Ineffective for children or older adults

Public health partners can take action.

See: Resources from Chris Voegeli

Questions

Q: How do we move past some of the vaccine fatigue?

Chris Voegeli (CDC): Message fatigue is especially bad. When we’re trying to message around data, one thing that seems to cut through at least fairly well are these more emotive storytelling testimonial messages. Other than that, I think it’s just about being judicious with the amount of messages we’re putting out and focusing on higher quality messages as opposed to the frequency of messages.

 

Q: Is there an area in the U.S. where these rumors originate or are generated? 

Chris Voegeli (CDC): I have no doubt that offline networks play a role in generating them. It’s just amazing when we see the prominent names on that list make a claim we then start seeing it pop up and many other places.

BACK TO TOP

Announcements
  • We need your feedback! The National Immunization Conference (NIC) will be held August 12–14, 2024 in Atlanta, GA. Following precedence, the National Adult and Influenza Immunization Summit (NAIIS) meeting will be held to coincide with the NIC, on August 15–16, 2024, with the meeting ending at 1PM on the 16th. In order to plan for the meeting, we are soliciting input from partners on their intentions to participate at the NIC and at the NAIIS. This input in very important so we would appreciate your feedback by December 29. Participate here: surveymonkey.com/r/3PGVMG6
  • There will be an upcoming webinar on adult immunizations and rural health; watch for more information
  • Immunize.org has a new streamlined look! Please feel free to give feedback: www.immunize.org/about/org/contact.
  • The Summit held a workshop on August 2nd to develop tools to address challenges in providing multiple adult vaccines along with COVID-19, flu, and RSV vaccines. Tools that address billing and insurance issues that go along with vaccinating patients were also developed. See the Summit’s Operationalizing Adult Immunizations in the 2023 Fall Season and Beyond Workshop web page for the deliverables. Note: some deliverables are in process of being finalized and uploaded to the website so check back for more.
  • If you are registered for the Summit and not getting the emails from Mailchimp, please add “NAIIS” at info@izsummitpartners.org to your contact list
  • If you have any agenda items that you are interested in sharing with the Summit, please let us know and we can add you to an upcoming call as a speaker or panelist. Contact information: info@izsummitpartners.org

BACK TO TOP

Print Friendly, PDF & Email

Search: